首页> 外文期刊>American Journal of Cardiovascular Disease >Critical role of mitochondrial ROS is dependent on their site of production on the electron transport chain in ischemic heart
【24h】

Critical role of mitochondrial ROS is dependent on their site of production on the electron transport chain in ischemic heart

机译:线粒体ROS的关键作用取决于它们在缺血性心脏电子传输链上的产生位点

获取原文
           

摘要

Abstract: Reactive oxygen species (ROS) generation has been implicated in many pathologies including ischemia/reperfusion (I/R) injury. This led to multiple studies on antioxidant therapies to treat cardiovascular diseases but paradoxically, results have so far been mixed as ROS production can be beneficial as a signaling mechanism and in cardiac protection via preconditioning interventions. We investigated whether the differential impact of increased ROS in injury as well as in protection could be explained by their site of production on the mitochondrial electron transport chain. Using amplex red to measure ROS production, we found that mitochondria isolated from hearts after I/R produced more ROS than non-ischemic when complex I substrate (glutamate/malate) was used. Interestingly, the substrates of complex II (succinate) and ubiquinone (sn-glycerol 3-phosphate, G3P) produced less ROS in mitochondria from I/R hearts compared to normal healthy hearts. The inhibitors of complex I (rotenone) and complex III (antimycin A) increased ROS production when glutamate/malate and G3P were used; in contrast, they reduced ROS production when the complex II substrate was used. Mitochondrial calcium retention capacity required to induce mitochondrial permeability transition pore (mPTP) opening was measured using calcium green fluorescence and was found to be higher when mitochondria were treated with G3P and succinate compared to glutamate/malate. Furthermore, Langendorff hearts treated with glutamate/malate exhibited reduced cardiac functional recovery and increased myocardial infarct size compared to hearts treated with G3P. Thus, ROS production by the stimulated respiratory chain complexes I and III has opposite roles: cardio-deleterious when produced in complex I and cardio-protective when produced in complex III. The mechanism of these ROS involves the inhibition of the mPTP opening, a key event in cell death following ischemia/reperfusion injury.
机译:摘要:活性氧(ROS)的产生已牵涉到多种病理,包括缺血/再灌注(I / R)损伤。这导致了对用于治疗心血管疾病的抗氧化剂疗法的多项研究,但自相矛盾的是,迄今为止的结果好坏参半,因为通过预处理干预,ROS的产生可以作为信号传导机制和对心脏的保护有益。我们调查了ROS的增加是否会对伤害和保护产生不同的影响,可以通过它们在线粒体电子传输链上的生成位置来解释。使用复数红测量ROS的产生,我们发现当使用复合I底物(谷氨酸/苹果酸)时,I / R后从心脏分离出的线粒体比非缺血产生的ROS多。有趣的是,与正常健康的心脏相比,复合物II(琥珀酸盐)和泛醌(3-磷酸正丁酯,G3P)的底物在I / R心脏的线粒体中产生的ROS更少。当使用谷氨酸/苹果酸和G3P时,复合物I(鱼藤酮)和复合物III(抗霉素A)的抑制剂增加了ROS的产生。相反,当使用复合物II底物时,它们减少了ROS的产生。使用钙绿色荧光测量了诱导线粒体通透性转换孔(mPTP)打开所需的线粒体钙保留能力,发现线粒体经G3P和琥珀酸处理后的线粒体钙保留能力高于谷氨酸/苹果酸。此外,与用G3P治疗的心脏相比,用谷氨酸/苹果酸治疗的Langendorff心脏表现出降低的心脏功能恢复和增加的心肌梗塞面积。因此,由刺激的呼吸链复合物I和III产生的ROS具有相反的作用:当在复合物I中产生时,对心脏不利,而在复合物III中产生时,对心脏有保护作用。这些ROS的机制涉及对mPTP开放的抑制,这是缺血/再灌注损伤后细胞死亡的关键事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号